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Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a
rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4).
Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of
the protein remains unknown. In this study, we report two cases of unrelated patients
presenting in the neonatal period with hyperlactacidemia and generalized hypotonia.
Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic
analysis showed one patient as having in compound heterozygosis a splice site variant
c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second
patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in
homozygosis. To validate the pathogenicity of these variants, molecular and
biochemical analyses were performed using skin-derived fibroblasts. We observed that
the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells
harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both
patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity
leading to diminished steady state levels of respiratory complex subunits, decreased
respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both
patients also revealed citrate synthase deficiency. Genetic complementation assays
established that the deficient phenotype was rescued by the canonical version of
FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts
allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and
augmented autophagy are associated with FBXL4 deficiency in cells, but are probably
secondary to a primary metabolic defect affecting oxidative phosphorylation.January 2020 | Volume 10 | Article 13001
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A dysfunction in the maintenance of the mitochondrial DNA
(mtDNA) leads to the reduction of mtDNA copy number and/or
the accumulation of defects in mtDNA. mtDNA depletion
syndromes (MDSs) are a group of mitochondrial disorders
characterized by a severe loss of mtDNA copy number. MDSs
are autosomal recessive disorders, genetically heterogeneous, and
clinically presented in encephalomyopathic, hepatocerebral or
myopathic forms (Suomalainen and Isohanni, 2010; Viscomi
and Zeviani, 2017).
The human mtDNA contains genetic coding information for
13 proteins, which are core constituents of the mitochondrial
respiratory complexes I, III, and IV (CI, CIII, and CIV) and the
F1F0-ATPsynthase [complex V (CV)]. The respiratory
complexes are embedded in the inner mitochondrial
membrane and function together with the tricarboxylic acid
(TCA) cycle in the matrix. The TCA cycle, together with the
beta oxidation of fatty acids, is pivotal for generation of NADH
and FADH2 to be oxidized by the respiratory chain. The electron
flux along the chain creates an electrochemical gradient that
powers the synthesis of most cellular ATP by CV [oxidative
phosphorylation (OxPhos)]. mtDNA depletion therefore causes
a combined respiratory chain deficiency and deficiency of
oxidative ATP-synthesis.
The study of pathogenic variants in patients with defects in
mtDNA maintenance has shown that this process depends on a
number of nuclear gene-encoded proteins that function in
mtDNA synthesis, either participating in mtDNA replication
or in the maintenance of balanced nucleotide pools, which
constitute the necessary building blocks (Suomalainen and
Isohanni, 2010). Qualitative defects in mtDNA (multiple
mtDNA deletions) can in addition be caused by defects in
mitochondrial division and fusion processes that influence
mtDNA segregation (El-Hattab et al., 2017a; Viscomi and
Zeviani, 2017).
Defects in F-box leucine-rich repeat 4 (FBXL4) protein, whose
molecular function has yet to be determined, cause an
encephalomyopathic type of MDS (MTDPS13; OMIM #
615471). MTDPS13 commonly presents with hypotonia,
psychomotor delay, failure to thrive, feeding difficulties, growth
failure, and lactic acidosis, among other less common
manifestations (El-Hattab et al., 2017a). The age of onset ranges
from birth to 2 years (mean 4 months). More than a third of
affected children die during childhood and long-term survivors
develop severe psychomotor retardation. In skeletal muscle tissue
commonly appear cytochrome oxidase (COX)-deficient fibers,
decreased activities of all respiratory chain enzymes, particularly
CI and CIV, and mtDNA depletion (El-Hattab et al., 2017a). The
study of cells derived from affected patients demonstrated that
FBXL4 is a mitochondrial protein controlling bioenergetic2homeostasis and mtDNA maintenance (Bonnen et al., 2013;
Gai et al., 2013). However, the molecular role of FBXL4 in
mtDNA maintenance remains unclear.
Here we report the identification of novel FBXL4mutations in
two independent patients and supported the causal role of those
mutations. The study of patient derived fibroblasts provided
some clues to understand the molecular function of the protein.MATERIALS AND METHODS
Cell Culture and Cell Staining With
Fluorescent Dyes
S1, S2, and C1 primary skin-derived fibroblasts were obtained
from Subject 1, Subject 2, and a 1 month-old control child,
respectively. C refers to mix of three primary fibroblasts from 1
month, 3 years and 38 years old controls, respectively. Cells were
cultured at 37°C under a 5% CO2 atmosphere in high-glucose
DMEMmedium (Gibco-ThermoFisher Scientific) with 10% fetal
bovine serum (FBS; Gibco-ThermoFisher Scientific).
Cell staining was performed in six well plates. Logarithmically
growing cells were incubated with FBS free DMEM for 30 min
at 37°C and then stained for 30 min at 37°C in the dark with
200 nM of either MitoTracker™ Green (Invitrogen) or
MitoTracker™ Red CMXRos (Invitrogen) in the culture
medium. For flow cytometry, immediately after staining, cells
were collected by trypsinization and 10,000 particles were
analyzed with a Beckman Coulter CITOMICS FC 500 Flow
Cytometer. For fluorescent microscopy, cells grown and stained
over cover-slides were fixed following a standard protocol and
images were obtained with a ZEISS HAL100 microscope.
Biochemical Analysis
Blood lactate values were determined by automated
spectrophotometry. Plasma amino acids and urine organic
acids were analyzed by ion exchange chromatography with
ninhydrin detection derivatives and gas chromatography/mass
spectrometry, respectively.
Genomic Analysis
Nuclear DNA (nDNA) was assessed by next generation
sequencing (NGS) using customized gene panels as previously
reported (Yubero et al., 2016; Fernandez-Marmiesse et al., 2019),
in a NextSeq500 sequencer (Illumina).
Alignment of FBXL4 Reference Sequences
Chordate FBXL4 reference sequences (243) were obtained from
GenBank (http://www.ncbi.nlm.nih.gov/genbank/) (accessed
July 22nd, 2019), and aligned with Clustal Omega (https://
www.ebi.ac.uk/Tools/msa/clustalo/).January 2020 | Volume 10 | Article 1300
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Complementation
The FBXL4 cDNA (corresponding to RefSeq NM_012160.4;
NP_036292.2) was amplified from retrotranscribed total RNA
of control and patient fibroblasts, as in (Emperador et al., 2014),
using the specific primers: Fw: GATATCGCCACCATGTC
ACCGGTCTTTCC and Rv: GATATCTCACTGAGTAA
AGCTC. After cloning with the TOPO™ PCR Cloning system
(Invitrogen), six to eight bacterial clones per cell line were
isolated and their plasmids sequenced.
For genetic complementation, a sequence checked clone,
obtained from control fibroblasts, was transferred to the
lentiviral expression vector pWPXLd-ires-NeoR, that is a
modified version of pWPXLd (Tronolab, Addgene #12258).
Lentiviral particles were generated as in (Perales-Clemente
et al., 2008) and fibroblasts were transduced with lentiviral
particles in 100 mm dishes by adding 10 ml of medium with
viral particles. Transduced cells were isolated by 10 days selection
in the presence of 400 mg/ml geneticin (Invitrogen-
ThermoFisher Scientific).
Real Time Quantitative Polymerase Chain
Reaction Experiments
mtDNA copy number was quantitated by quantitative
polymerase chain reaction (qPCR) as previously described
(Andreu et al., 2009), using a StepOne™ Real-Time PCR
System (Applied Biosystems™). The mitochondrial probe,
labeled with a FAM fluorophore, was targeted to the MT-
RNR1 gene (TGC CAG CCA CCG CG) and the nuclear probe,
labeled with a VIC was targeted to the RNAsa P gene.
To assess mitochondrial mRNA levels, total RNA was isolated
from exponentially growing cells using a NucleoSpin® RNA II kit
(Macherey-Nagel). Total RNA (1 mg) was reversed-transcribed
(RT) with the Transcriptor First Strand cDNA Synthesis Kit
(Roche). The levels of MT-ND1, MT-ND6, MT-CYB, MT-CO1,
and MT-ATP6 were determined by RT-qPCR using the One-
Step Real-Time system (Applied Biosytems). The expression
levels were normalized using the 18S ribosomal RNA. The
DDCt method was used to calculate fold expression. StepOne
software version 2.0 (Applied Biosystems) was used for data
analysis. To quantify FBXL4 transcripts qPCR was carried out in
a LightCycler 2.0 system (Roche), using the specific primers:
q F w : T GAGATGTGTCCAAATCTACAGG a n d
qRv: GCTGAGCAGTGCTGTTTGC.
SDS-PAGE and Western Blot Analysis
For Western blotting (WB), 20 mg of either total cellular protein
extracted in RIPA buffer (MILLIPORE), or total cell homogenate
treated by freeze-thawing (4X) (for LC3B WB) was separated in
12.5% acrylamide/bis-acrylamide SDS/PAGE, electroblotted
onto PVDF filter, and sequentially probed with specific
antibodies: anti-FBXL4 (Sigma, #SAB2701256), anti-OXPHOS
cocktail (Abcam, #ab110411), anti-SDHA (Thermo Fisher
Scientific, #459200), anti-Actin (Sigma, #A 2066), anti-CS
(Sigma, # SAB2702186), anti-TOMM20 (SantaCruz
biotechnology, Inc., #sc-11415), and anti-LC3B (Sigma,Frontiers in Genetics | www.frontiersin.org 3#L7543). Luminescence images were acquired using Amersham
Imager 600 (GE Healthcare Life Sciences) and quantitative data
were obtained with ImageQuant™ TL 8.1 analysis software.
Complex IV Levels and Complex IV and
Citrate Synthase Specific Activities
When Microplate Assays were indicated, complex IV (CIV)
activity and levels were measured using the CIV Specific
Activity Microplate Assay Kit (Mitosciences, Abcam®),
according to the manufacturer's instructions, and CS was
measured in 96 well plates, using freeze-thawing treated total
cell homogenate and a standard protocol (Kirby et al., 2007).
Microplate assays were performed in a NovoStar MBG Labtech
microplate instrument. Otherwise, CIV and CS activities were
measured in an UNICAM UV 500 spectrophotometer using
digitonin (Sigma) solubilized cell samples as described previously
(Kirby et al., 2007). Activity data were normalized for
total protein.
ATP Measurements
ATP levels were measured using the ATP bioluminescence assay
kit CellTiter-Glo® Luminescent Cell Viability Assay (Promega),
according to the manufacturer's instructions. Values were
normalized using the CellTiter-Blue® Cell Viability Assay
(Promega) according to the manufacturer's instructions.
Samples were measured using a NovoStar MBG Labtech
microplate instrument.
Statistical Analysis
The statistical package StatView 6.0 was used to perform the
statistical analysis. Data are expressed as mean ± SD (standard
deviation). The non-parametric Mann-Whitney test was used to
evaluate the statistical significance between experimental groups.
P-values lower than 0.05 were considered statistically significant.
All samples were measured at least in biological triplicates.RESULTS
Subject Description
S1: This female child, born to nonconsanguineous parents of
European ancestry, was delivered at 38 weeks gestation with a
very low weight for gestational age (2.650 kg, < 1st percentile).
Fetal ultrasounds also reported a single umbilical artery and
megacisterna magna. In the first days of life, mild hypotonia and
nystagmus triggered by Moro reflex were observed. Blood lactate
was repeatedly increased (4.8 to 11.3 mmol/L; reference values
(RV) < 2.2) along with alanine. Brain magnetic resonance image
(MRI) revealed mild cerebellar hypoplasia and probable bilateral
simplified temporal and frontal gyration pattern. These results
led to the study of mitochondrial disease. At 2 months of age, she
had frequent visits to the Emergency Department due to
intercurrent respiratory processes. Psychomotor development
was delayed with poor eye contact and hypotonia. At 6 months
of age, she presented with infantile spasms (West syndrome) that
responded to treatment with vigabatrin and prednisolone. Due toJanuary 2020 | Volume 10 | Article 1300
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was initiated. In addition, she had gastroesophageal reflux with
frequent vomiting. She presented with progressive dysphagia
with poor control of respiratory secretions, convergent
strabismus as well as brain MRI lesions compatible with Leigh
syndrome. At 10 months, there was an episode of aspiration with
marked deterioration in her general condition, generalized
hypotonia and seizures. A worsening of the brainstem lesions
was observed on brain MRI. The symptoms were progressive
with encephalopathy, metabolic acidosis, and death.
S2: This male child, born to consanguineous parents of
Moroccan ancestry, was delivered by caesarean section due to
arrest of dilation at 38.4 weeks gestation with a low weight for
gestational age (2.650 kg, 8th percentile), short length for
gestational age (47 cm, 5th percentile), and normal head
circumference (34 cm, 43rd percentile). On the third day of life,
he showed an acute neurological and respiratory worsening with
cyanosis and hypotonia. The patient was intubated and
ventilated. Physical examination showed clinical signs of poor
peripheral perfusion and absence of responses to stimuli due to
sedoanalgesia. On admission, he presented with metabolic
acidosis (pH 7.13, pCO2 22.2 mmHg on mechanical ventilation,
stHCO3 8.9 mmol/L, EB –20.6 mmol/L), hyperamonemia (224
µmol/L: RV <70), and hyperlactacidemia (25 mmol/L: RV < 2.2).
Plasma amino acids exhibited increased alanine (1385 µmol/L:
RV 190–337), glycine (658 µmol/L: RV 180–291), glutamine (971
µmol/L: RV 420–750), and lysine (705 µmol/L: RV 67–202).
Organics acids revealed a massive accumulation of lactic, 3-
hydroxybutyric, acetoacetic, and 2-hydroxybutyric acids,
leading to investigate mitochondrial diseases. No analytical
signs of infection were detected. Transfontanellar ultrasound
showed extensive hyperechogeneity that seemed to correspond
to retro cerebellar hemorrhage and enlarged magna cisterna. No
brainMRI or lumbar puncture was performed. Echocardiography
showed pulmonary hypertension.
Different treatment approaches were initiated to correct the
metabolic abnormalities: protein restriction, high energy intake
(100–120 cal/kg/day), L-carnitine, arginine, and vitamins (biotin,
hydroxycobalamin, pyridoxine, riboflavin, and thiamine). An
intravenous insulin and dopamine (maximum dose 5 µg/kg/
min) pump and antibiotics (ampicillin and gentamicin) were also
started. He received several doses of intravenous bicarbonate and
three doses of adrenaline for severe bradycardia. At 24 hours of
admission, there was a limitation of the therapeutic effort due to
the refractoriness of lactic acidosis. The child died at the age of
4 days.
Although some dysmorphisms have been reported in
FBXL4 patients, microcephaly, cataracts, malformed ears, or
other dysmorphic facial features were not found in S1 or S2
patients. However, S2 showed distal hypospadias and
bilateral cryptorchidism.
Biallelic Mutations in FBXL4 Are Present in
the Probands
Exome sequencing analysis of S1 and S2 detected novel mutations
in FBXL4 (Figure 1A). S1 was found to be compoundFrontiers in Genetics | www.frontiersin.org 4heterozygous for the split site variant c.858+5G>C and the
missense variant c.1510T>C (p.Cys504Arg). The first variant
was detected in the father and the second in the mother. S2 was
found to be homozygous for the frameshift variant c.851delC
(p.Pro284LeufsTer7), that was detected in both parents in
heterozygosis. The variants were confirmed by Sanger sequencing.
Patient RNA-retrotranscription and cDNA cloning revealed
two classes of FBXL4 transcripts in S1 (Figure 1A). One
transcript harbored the missense variant c.1510T>C
(p.Cys504Arg) and a second one lacked exon 4, which can be
compatible with a splicing defect. The analysis of S2 detected
only one type of transcript harboring the frameshift variant
c.851delC (p.P284LfsTer7) (Figure 1A).
None of these variants were present in the ExAC browser
(accessed July 2019). However, the variant producing an
unexpected transcript in S1 has been previously published in
heterozygosis in a patient with MTDPS13 (rs1257765682)
(Pronicka et al., 2016). The S1 missense variant affects a
position conserved in 243 out of 243 reference sequences and is
considered pathogenic by several prediction software packages
(MutationTaster, PMut and PolyPhen-2). Eighteen months after
the death of S1, the parents had a healthy girl that was not a carrier
of either of the two mutations. Two years later, the parents had a
new twin pregnancy. The amniocentesis of both fetus revealed
that they were only carriers of the c.858+5G>C variant inherited
from the father. At 2-years of age, both of them are healthy.
Defective OxPhos System Biogenesis
Is Associated With the Novel
FBXL4 Mutations
Analysis of mtDNA copy number revealed severe mtDNA
depletion in muscle biopsies of the patients (85% in S1 and
93% in S2). In cultured skin fibroblasts, milder mtDNA depletion
was detected in S1 (38%) whereas normal levels of mtDNA were
observed in S2 (Figure 1B). The levels of five mitochondrial
transcripts (transcripts of MT-ND1 and MT-ND6 subunits from
CI; MT-CYB subunit from CIII, MT-CO1 subunit from CIV and
MT-ATP6 subunit from CV) were consistently reduced in S1 and
S2 compared with control fibroblasts (Figure 1C). Notably, S2,
with normal mtDNA copy number, showed the highest
reduction of the five transcripts measured.
The steady-state levels of subunits from respiratory chain
complexes were also found decreased in fibroblasts from S1, and,
to a greater extent, in fibroblasts from S2 (Figure 1D). The levels
of the nDNA-encoded ATP5A subunit from CV, however,
remained unchanged in S1, or were mildly decreased in S2,
excluding a global problem in the mitochondrial protein content.
The expression of two subunits (SDHA and SDHB) of the
nuclear encoded complex II, the citrate synthase (CS) of the
TCA cycle, and the translocase of the outer mitochondrial
membrane (TOMM20) were partially decreased in S2 (Figure
1D). Fully assembled CIV levels were clearly lower in patient
fibroblasts relative to controls (Figure 1E). Enzymatic
measurements provided evidenced of a severe CIV dysfunction
(Figure 1F). Noteworthy, the CS activity in fibroblasts from S1
and S2 was also significantly diminished (Figure 1F).January 2020 | Volume 10 | Article 1300
Emperador et al. Pathological Variations in FBXL4FIGURE 1 | Genetic, molecular, and biochemical characterization of the patients. (A) Pedigrees of S1 and S2 with genotypes indicated under each symbol (black
symbols designate affected subjects); sequencing electropherograms corresponding to the two different FBXL4-derived transcripts found in S1 and to the unique
transcript found in S2; and FBXL4 gene structure (reference sequence NM_012160.4). In gene structure, empty boxes: non-coding exons; dark blue boxes: F-Box
domain; striped boxes: leucine-rich repeats domain (LRRs). (B) Quantification of mtDNA copy number. The bars represent percentage of mtDNA normalized to
nDNA relative to the mean value of controls levels (C, dotted line, 100%). *: Significant mtDNA copy-number reduction, p < 0.05, compared with C cells.
(C) Mitochondrial transcript levels. For each transcript, the bars represents mean values, in percentage, relative to the mean value of control fibroblasts (C, dotted
line, 100%). *: significant mtDNA reduction, p < 0.05, compared with C cells. (D) Steady-state levels of mitochondrial respiratory chain subunits. WB-
immunodetection of SDS-PAGE separated total cellular protein isolated from patient S1, S2 and C fibroblasts (−), and those transduced with wt-FBXL4 expressing
construct (+). An OXPHOS cocktail of antibodies was used in the upper membrane (blot 1) and the indicated antibodies were sequentially used in the lower
membrane (blot 2). (E) Complex IV quantity (Microplate Assay). The bars represent the mean value of S1 and S2, in percentage, compared to that of controls
fibroblasts (dotted line, 100%). *: p < 0.05 (vs. C cells). (F) Complex IV (CIV) and CS specific activities (s.a.) (Microplate Assay). The bars represent enzymatic activity
of CIV and CS normalized for total cellular protein and compared to the mean value of controls fibroblasts in percentage (dotted line, 100%). *: p < 0.05 (vs. C cells).Frontiers in Genetics | www.frontiersin.org January 2020 | Volume 10 | Article 13005
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mtDNA-encoded genes affects the correct biogenesis and
function of the respiratory chain, with the TCA-cycle enzyme
CS also affected.
Delivery of Wild-Type FBXL4 Corrects the
OxPhos Dysfunction
In order to confirm the pathogenicity of the FBXL4 mutations,
we performed genetic complementation studies. Stably
transduced patient cells showed a robust expression of wild-
type FBXL4 (wt-FBXL4) at transcript and protein levels (Figures
2A, B). The quantification of FBXL4 transcripts by qRT-PCR
revealed decreased steady-state levels of FBXL4mRNA in S1 and
S2 by approximately 80% when compared with an age matched
control cell line, C1. These levels were increased significantly in
the over-expressing cell lines (Figure 2A). The WB-
inmunodetection assay failed to detect the FBXL4 protein in
the total protein lysate of non-transduced cells (Figure 2B).
Delivery of the wt-FBXL4 gene increased significantly the
amount of mtDNA in both patient cell lines (Figure 2C). As a
result, the mtDNA copy number deficiency in S1 cells was
corrected (compared to C), whereas in S2 cells the mtDNA
levels increased up to 200% of the levels of controls. In both S1
and S2 cells over-expressing wt-FBXL4, the steady state levels of
respiratory complex subunits were fully rescued (Figure 1D), the
CIV specific activity was increased to control values (Figure 2D),
and the CS activity and lastly the mitochondrial ATP levels were
also increased significantly (Figures 2E, F).
These results confirmed the causal role of the mutations
identified in FBXL4 in the metabolic dysfunction.
Mitochondrial Mass, Mitochondrial
Fragmentation, and Autophagosomes Are
Increased in FBXL4 Deficiency
Next, we investigated the mitochondrial mass in cultured patient
fibroblasts to determine whether it is reduced as could be
suggested by the low CS activity. Assessment of mitochondrial
content by staining with the cationic lipophilic dye MitoTracker
Green failed to show differences between C1 and wt-FBXL4
overexpressing C1 cells (Figure 3A). However, a small but
significant increase in mitochondrial content (15–20%) was
detected in S1 and complemented S1 cell lines compared to
C1, and a remarkable increase (250% of C1) was detected in S2
fibroblasts and in the S2 cell line overexpressing wt-FBXL4.
The mitochondrial network morphology was next examined.
As shown in the fluorescence microscopy images (Figure 3B),
the fluorescent pattern obtained with the mitochondrion-specific
dye MitoTracker was mainly tubular in C1 cells. On the contrary,
S1 and S2 cell lines showed fragmentation of the mitochondrial
network. Genetically complemented S1 cells recovered partially
the tubular appearance of the mitochondrial network observed in
C1 but interestingly, genetically complemented S2 cells
maintained a fragmented mitochondrial network.
The autophagosome marker MAP1 light chain 3B (LC3B) can
be found as LC3B-I, mainly cytosolic, or as LC3B-II, which isFrontiers in Genetics | www.frontiersin.org 6covalently attached to phosphatidylethanolamine and coats the
sur face of autophagosomes . Western blot t ing and
immunodetection were used to analyze LC3B-I to LC3B-II
conversion and estimate the abundance of autophagy-related
structures (Klionsky et al., 2008). The ratio LC3B-II/LC3B-I was
found augmented in S1 and S2 cells (Figure 3C). Albeit in
genetically complemented S1 cells, the ratio was reduced to the
control levels; in genetically complemented S2 cells, however, the
significantly high levels of autophagy marker LC3-II related to its
cytosolic isoform LC3-I persisted.
These results suggested that mitochondrial fragmentation and
an increase of autophagosomes are associated with FBXL4
mutations in cultured fibroblasts. Remarkably, the genetically
complemented S2 cell line failed to recover normal
mitochondrial size or shape and normal autophagy levels,
suggesting that these are secondary adaptations to the
metabolic dysfunction promoted by FBXL4 deficiency.DISCUSSION
This work presents two patients with severe encephalopathy and
severe mtDNA depletion in muscle associated with novel variants
in FBXL4; S1 harboring two variants in compound heterozygosis
c.[858+5G>C];[1510T>C] and S2 harboring one variant in
homozygosis c.[851delC];[851delC]. The pathogenicity of the
variants was confirmed by genetic complementation assays in
skin-derived fibroblasts. Genetic complementation studies with
this gene have only been performed in three subjects previously
(Bonnen et al., 2013; Gai et al., 2013).
A review of genotype–phenotype correlation in 87 affected
individuals with pathological variants in FBXL4 indicated that
genotypes with missense variants are frequently associated with
longer survival (El-Hattab et al., 2017b). Thus, the missense
variant encountered in S1 could be associated with preservation
of some residual protein function and therefore with a milder
phenotype. However, both patients presented with very severe
clinical phenotype associated with very early onset and short
survival (S1, 10 months, and S2, 4 days), indicating that any
possible residual function of the S1 missense variant was not
sufficient to maintain in vivo protein function.
The finding of severe mtDNA depletion in skeletal muscle
biopsies (85% in S1 and 93% in S2) are in line with published
data indicating an essential role of FBXL4 in the maintenance of
mtDNA. Interestingly, important differences were observed in
the mtDNA content of cultured fibroblasts. S1 cells presented
with quantitative mtDNA copy number reduction (38%),
whereas S2 cells had normal mtDNA copy number.
Remarkably, genetic complementation increased the mtDNA
levels in at least 50%, still indicating an involvement of FBXL4
in mitochondrial mtDNA copy number maintenance. Despite
having normal mtDNA content, S2 derived fibroblasts showed a
more severe OxPhos deficient phenotype than S1 cells. The levels
of mtDNA-derived transcripts were lower than those in S1, and
several subunits of the respiratory chain complexes were absent.
Thus, mtDNA levels did not correlate with mitochondrial RNAJanuary 2020 | Volume 10 | Article 1300
Emperador et al. Pathological Variations in FBXL4levels as expected (Gomez-Duran et al., 2012) indicating that
FBXL4 deficiency also affects the correct mtDNA expression.
The patient primary fibroblasts showed augmented
mitochondrial mass, when assessed by MitoTracker Green
fluorescent staining. The increase was particularly high in S2
cells. It can be speculated that FBXL4 deficient fibroblasts
might have overcome the defect in mtDNA maintenance by
expanding their mitochondrial mass as an adaptation to the life
in culture. An attempt to compensate for OxPhos defects
increasing mitochondrial mass resembles the massive
mitochondrial proliferation observed in muscle of patients withFrontiers in Genetics | www.frontiersin.org 7mtDNA-related diseases (resulting in ragged-red fibers)
(DiMauro and Schon, 2003). However, in muscle from FBXL4
deficient patients no ragged red fibers have been observed (Gai
et al., 2013; Morton et al., 2017), although they are a common
feature in newborns and infants with mitochondrial disorders
(Jou et al., 2019).
Previous patient reports have described a hyperfragmentation
of the mitochondrial network in affected fibroblasts (Bonnen
et al., 2013; Gai et al., 2013; Antoun et al., 2016). This has lead to
classify FBXL4 as protein participating in mitochondrial
dynamics (El-Hattab et al., 2017a). The highly compactedFIGURE 2 | FBXL4 complementation assays. (A) FBXL4 expression levels. Bars represent FBXL4 mRNA levels of patient fibroblasts compared to the mean value of
an age-matched control in percentage (C1 dotted line, 100%). *: p < 0.05 (vs. C1 cells); #: p < 0.05 (vs. non-transduced cells). (B) FBXL4 protein levels. WB-
immunodetection with anti-FBXL4 antibody of total cellular proteins isolated from S1, S2, and C1 fibroblasts, and those transduced with wt-FBXL4 expressing
construct. (C) Quantification of mtDNA copy number of S1, S2, and C1 fibroblasts and those transduced with the wt-FBXL4 expressing construct. Bars represent
the mean value of mtDNA normalized to nDNA, in percentage, relative to the mean value of controls levels (C, dotted line, 100%). *: p < 0.05 (vs. C cells); #: p < 0.05
(vs. non-transduced cells). (D) Complex IV specific activity of S1, S2, and C1 fibroblasts and of those transduced with the wt-FBXL4 expressing construct. Bars
represent the mean value relative to that of control fibroblasts in percentage (C1, dotted line, 100%). *: p < 0.05 (vs. C1 cells). (E) CS specific activity of S1, S2, and
C fibroblasts and those transduced with the wt-FBXL4 expressing construct. Bars represent the mean value relative to that of control fibroblasts, in percentage (C1,
dotted line, 100%). *: p < 0.05 (vs. C1 cells); #: p < 0.05 (vs. non-transduced cells). (F) Mitochondrial ATP levels. Bars represent the mean values in S1, S2 and C1,
S1 and S2 transduced with the wt-FBXL4 expressing construct, relative to that of control cells in percentage (C1, dotted line, 100%). *: p < 0.05 (vs. C1 cells);
#: p < 0.05 (vs. non-transduced cells).January 2020 | Volume 10 | Article 1300
Emperador et al. Pathological Variations in FBXL4mtDNA–protein complexes or nucleoids, that usually can be
visualized as punctate structures evenly distributed within the
mitochondrial network, have also been found altered, enlarged,
and clustered (Bonnen et al., 2013). Our patients' fibroblasts also
presented a mitochondrial network fragmented into multiple
small mitochondria. Interestingly, S1 fibroblasts partially
recovered a connected mitochondrial network when
functionally complemented with wt-FBXL4 , whereas
mitochondria in S2 complemented fibroblasts remained mostly
punctuate. These findings suggest that mitochondrial
fragmentation could be secondary to the metabolic defects
induced by absence of the FBXL4 protein. Augmented
mitochondrial division could be related with attempts to
increase mtDNA synthesis because both processes are closely
related. In mammalians, tubular ER-mitochondria contacts, by
an unknown mechanism, connect the sites of mitochondrial
division with the subset of nucleoids engaged in mtDNA
synthesis. Thus, following division, nucleoids segregate to both
tips of daughter mitochondria (Lewis et al., 2016). This fact,
however, could not be confirmed in our studies.
Increased mitochondrial division can also precede mitophagy,
because it divides elongated mitochondria into pieces that can be
engulfed by autophagosomes to regulate their number and
maintain quality control (Youle and Narendra, 2011). Both S1
and S2 fibroblasts demonstrated increase of the autophagic-vesiclesFrontiers in Genetics | www.frontiersin.org 8coating-protein LC3B-II, suggesting that FBXL4 deficiency
promotes autophagic processes. In genetically complemented S1
cells autophagosome formation decreased. It could be speculated
that it reflects the need for selective elimination of the organelles
lacking a functional OxPhos system and/or the necessity of
recycling intracellular components to compensate for the
starvation-like situation (Geng and Klionsky, 2008). The
reduction of mitochondrial components other than subunits of
the respiratory chain clearly observed in S2 can be reflecting its
elimination by mitophagy. In genetically complemented S2 cells,
the increased autophagy persisted possibly regulating the organelle
number since the abnormally high increase in mitochondrial
membrane also persisted.
In contrast to patients with typical MDSs due to a disorder of
mtDNA replication or nucleoside salvage/synthesis, in patients
with FBXL4 deficiency the mtDNA/CS ratio is normal (Huemer
et al., 2015). Our patient cells also presented CS deficiency. It can
be a secondary effect, because interruptions to the respiratory
chain can affect the TCA cycle flux (Vafai and Mootha, 2012).
Deficiency in another TCA cycle enzyme, succinyl-CoA
synthetase (SCS), has also been associated with an
encephalomyopathic form of MDS. However, the involvement
of SCS in MDS seems to be related to a role of the enzyme in the
mitochondrial nucleoside salvage pathway, facilitating the
conversion of dNDPs to dNTPs (Viscomi and Zeviani, 2017).FIGURE 3 | Mitochondrial network shape and size, and autophagy detection. (A) Quantification of mitochondrial mass. Bars represent the mean fluorescence values
relative to the mean value of age-matched control fibroblasts in percentage (C1, dotted line, 100%). *: p < 0.05 (vs. C1 cells). (B) Mitochondrial networks of control
and patients fibroblasts. Fluorescence microscopy representative images of cells obtained from control and patient fibroblasts and of those transduced with the wt-
FBXL4 expressing construct, as indicated. (C) Quantification of autophagy marker LC3-II. WB-immunodetection of the LC3B isoforms (LC3B-I and LC3B-II) of total
cell homogenates, and ratio LC3B-II/LC3B-I obtained by quantification of the respective WB-band intensities. The bars represent the mean value, in percentage,
compared to that of control fibroblasts (dotted line, 100%). *: p < 0.05 (vs. C1 cells).January 2020 | Volume 10 | Article 1300
Emperador et al. Pathological Variations in FBXL4In summary, this work provides evidence of the pathogenicity
of novel variants in FBXL4, demonstrating that FBXL4 is
necessary not only for the homeostasis but also for the
expression of mtDNA. Since in S2 fibroblasts the rescue of the
bioenergetics defects by the FBXL4 gene can occur independently
of the recovery of control mitochondrial mass, mitochondrial
network, or autophagic levels, these could be compensatory and
subsequent to the bioenergetic defects. Most F-box proteins
function as adaptors in phosphorylation dependent
ubiquitination-complexes (Craig and Tyers, 1999). A role in
post-translational modification of the mitochondrial proteome
could reconciled the disparity of effects observed in defective
FBXL4, but further work is required to determine the precise
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